|Last Price$7.06||Day Change (%)-2.62%|
|Open Price$7.18||Day Change ($)-0.19|
|Day Range7.01–7.42||52-Week Range3.10–7.57|
As of Mon 12/22/2014 12:13 PM EST | USD
More Than 150 Companies Expected to Present at the 17th Annual BIO CEO & Investor Conference
Progenics Pharmaceuticals PGNX and partner Wyeth WYE announced Thursday that both the Food and Drug Administration and the European Medicines Agency have accepted new drug applications for subcutaneous MNTX, which aims to treat postoperative ileus and opioid bowel dysfunction. We are leaving our ...
Progenics Pharmaceuticals PGNX announced on March 6 that it would backtrack and reformulate the oral version opioid bowel dysfunction drug MNTX to make it more effective. If successful, the firm could file for its approval in late 2009. Our fair value estimate remains unchanged, as we'd already ...